Compare Salesforce Inc (CRM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Nuwellis Inc — how do they compare? Salesforce Inc trades at $170.16 (market cap $137.23B), while Nuwellis Inc trades at $3.2 (market cap $1.17M). The key difference: Salesforce Inc is far larger — about 117290.6× Nuwellis Inc's market cap, and Salesforce Inc pays a 1.05% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| CRM | NUWE | |
|---|---|---|
Market Cap | $137.23B | $1.17M |
Sector | Technology | Technology |
52-Week High | $270.25 | $558.26 |
52-Week Low | $150.12 | $2.80 |
Enterprise Value | $167.28B | -$636.97K |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.28, showing minimal daily movement (+0.04%) amid recent market volatility. The stock demonstrates strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while the stock trades near key support at $170. Recent news highlights AI momentum and market concerns about software sector performance.
CRM presents a compelling investment case with strong analyst support (76.84% buy rating) and significant upside to the $235.90 consensus target. However, investors face risks from sector-wide software selloffs, competitive AI landscape pressures, and the stock's 35% YTD decline requiring careful evaluation of growth sustainability versus current valuation discounts.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
